[go: up one dir, main page]

NO20072399L - New pyrrolo [3,2-d] pyrimidin-4-o derivatives and their use in therapy - Google Patents

New pyrrolo [3,2-d] pyrimidin-4-o derivatives and their use in therapy

Info

Publication number
NO20072399L
NO20072399L NO20072399A NO20072399A NO20072399L NO 20072399 L NO20072399 L NO 20072399L NO 20072399 A NO20072399 A NO 20072399A NO 20072399 A NO20072399 A NO 20072399A NO 20072399 L NO20072399 L NO 20072399L
Authority
NO
Norway
Prior art keywords
therapy
pyrimidin
derivatives
new pyrrolo
new
Prior art date
Application number
NO20072399A
Other languages
Norwegian (no)
Inventor
Anna-Karin Tiden
Anders Bogevig
Yvonne Lo-Alfredsson
Donald Pivonka
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=36578191&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NO20072399(L) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from SE0402972A external-priority patent/SE0402972D0/en
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Publication of NO20072399L publication Critical patent/NO20072399L/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/12—Mucolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Pulmonology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Rheumatology (AREA)
  • Urology & Nephrology (AREA)
  • Cardiology (AREA)
  • Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Vascular Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Det blir beskrevet nye forbindelser med formel (I), hvori R1, R12, L, X og Y er som definert i beskrivelsen, og farmasøytisk akseptable salter derav, sammen med fremgangsmåter for fremstilling av dem, preparater som inneholder dem, og anvendelse av dem i terapi. Forbindelsene er inhibitorer av enzymet MPO og er derved særlig anvendelige ved behandling eller profylakse av nevroinflammatoriske forstyrrelser, kardiovaskulære forstyrrelser og respiratoriske forstyrrelser.New compounds of formula (I) are disclosed, wherein R 1, R in therapy. The compounds are inhibitors of the enzyme MPO and are thus particularly useful in the treatment or prophylaxis of neuroinflammatory, cardiovascular and respiratory disorders.

NO20072399A 2004-12-06 2007-05-10 New pyrrolo [3,2-d] pyrimidin-4-o derivatives and their use in therapy NO20072399L (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
SE0402972A SE0402972D0 (en) 2004-12-06 2004-12-06 Novel compounds
SE0501093 2005-05-13
PCT/SE2005/001835 WO2006062465A1 (en) 2004-12-06 2005-12-05 Novel pyrrolo [3, 2-d] pyrimidin-4-one derivatives and their use in therapy

Publications (1)

Publication Number Publication Date
NO20072399L true NO20072399L (en) 2007-08-24

Family

ID=36578191

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20072399A NO20072399L (en) 2004-12-06 2007-05-10 New pyrrolo [3,2-d] pyrimidin-4-o derivatives and their use in therapy

Country Status (29)

Country Link
US (3) US7829707B2 (en)
EP (1) EP1824855B1 (en)
JP (1) JP5028270B2 (en)
KR (3) KR101412786B1 (en)
CN (1) CN101072778B (en)
AR (1) AR051698A1 (en)
AU (1) AU2005312388B2 (en)
BR (1) BRPI0518846B1 (en)
CA (1) CA2591314C (en)
CY (1) CY1113209T1 (en)
DK (1) DK1824855T3 (en)
ES (1) ES2390888T3 (en)
HR (1) HRP20120781T1 (en)
IL (1) IL183182A (en)
ME (1) ME01486B (en)
MX (1) MX2007006497A (en)
MY (1) MY140748A (en)
NO (1) NO20072399L (en)
NZ (1) NZ555046A (en)
PL (1) PL1824855T3 (en)
PT (1) PT1824855E (en)
RS (1) RS52490B (en)
RU (2) RU2577858C2 (en)
SA (1) SA05260385B1 (en)
SI (1) SI1824855T1 (en)
TW (1) TWI365189B (en)
UA (1) UA89968C2 (en)
UY (1) UY29246A1 (en)
WO (1) WO2006062465A1 (en)

Families Citing this family (63)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR039385A1 (en) 2002-04-19 2005-02-16 Astrazeneca Ab THIOXANTINE DERIVATIVES AS INHIBITORS OF MIELOPEROXIDASA
MY140748A (en) 2004-12-06 2010-01-15 Astrazeneca Ab Novel pyrrolo [3,2-d] pyrimidin-4-one derivatives and their use in therapy
US8809310B2 (en) * 2006-02-21 2014-08-19 Teva Pharmaceutical Industries, Ltd. Use of rasagiline for the treatment of multiple system atrophy
UY30267A1 (en) * 2006-04-13 2007-11-30 Astrazeneca Ab NEW DERIVATIVES OF THIOXANTINE, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM, PREPARATION PROCEDURES AND APPLICATIONS
WO2007120097A1 (en) * 2006-04-13 2007-10-25 Astrazeneca Ab Thioxanthine derivatives and their use as inhibitors of mpo
TW200804383A (en) 2006-06-05 2008-01-16 Astrazeneca Ab New compounds
US20090054468A1 (en) * 2007-08-23 2009-02-26 Astrazeneca Ab New Use 938
JP5201063B2 (en) * 2008-04-15 2013-06-05 信越化学工業株式会社 Addition-curing silicone composition and cured product thereof
EP2411393B1 (en) 2009-03-23 2014-01-22 Glenmark Pharmaceuticals S.A. Fused pyrimidine-dione derivatives as trpa1 modulators
GB0913345D0 (en) 2009-07-31 2009-09-16 Astrazeneca Ab New combination 802
WO2011061527A1 (en) 2009-11-17 2011-05-26 Astrazeneca Ab Combinations comprising a glucocorticoid receptor modulator for the treatment of respiratory diseases
TWI527814B (en) 2010-12-16 2016-04-01 健生科學愛爾蘭無限公司 Azabenzimidazoles as respiratory syncytial virus antiviral agents
TWI515187B (en) 2010-12-16 2016-01-01 健生科學愛爾蘭無限公司 Anthraquinone as an antiviral agent for respiratory fusion virus
TWI501967B (en) 2010-12-16 2015-10-01 Janssen R&D Ireland Azaindoles as respiratory syncytial virus antiviral agents
WO2012088266A2 (en) 2010-12-22 2012-06-28 Incyte Corporation Substituted imidazopyridazines and benzimidazoles as inhibitors of fgfr3
GB201021979D0 (en) 2010-12-23 2011-02-02 Astrazeneca Ab New compound
GB201021992D0 (en) 2010-12-23 2011-02-02 Astrazeneca Ab Compound
BR112014011254A2 (en) 2011-11-11 2017-05-16 Pfizer 2-thiopyrimidinones
WO2013150115A1 (en) * 2012-04-05 2013-10-10 Basf Se N- substituted hetero - bicyclic compounds and derivatives for combating animal pests
NZ702747A (en) 2012-06-13 2017-03-31 Incyte Holdings Corp Substituted tricyclic compounds as fgfr inhibitors
DK2864323T3 (en) 2012-06-15 2017-08-14 Janssen Sciences Ireland Uc 1,3-DIHYDRO-2H-BENZIMIDAZOLE-2 UNDERIVATIVES SUBSTITUTED BY HETEROCYCLES AS ANTIVIRUS AGENTS AGAINST RESPIRATORY SYNCYTIAL VIRUS
WO2014026125A1 (en) 2012-08-10 2014-02-13 Incyte Corporation Pyrazine derivatives as fgfr inhibitors
US9266892B2 (en) 2012-12-19 2016-02-23 Incyte Holdings Corporation Fused pyrazoles as FGFR inhibitors
LT2986610T (en) 2013-04-19 2018-04-10 Incyte Holdings Corporation Bicyclic heterocycles as fgfr inhibitors
US9920075B2 (en) 2014-09-11 2018-03-20 Bristol-Myers Squibb Company Triazolopyridine and triazolopyrimidine inhibitors of myeloperoxidase
US10851105B2 (en) 2014-10-22 2020-12-01 Incyte Corporation Bicyclic heterocycles as FGFR4 inhibitors
US9616063B2 (en) * 2014-12-01 2017-04-11 Astrazeneca Ab 1-[2-(aminomethyl)benzyl]-2-thioxo-1,2,3,5-tetrahydro-4H-pyrrolo[3,2-d]pyrimidin-4-ones as inhibitors of myeloperoxidase
MA41551A (en) 2015-02-20 2017-12-26 Incyte Corp BICYCLIC HETEROCYCLES USED AS FGFR4 INHIBITORS
US9580423B2 (en) 2015-02-20 2017-02-28 Incyte Corporation Bicyclic heterocycles as FGFR4 inhibitors
SG10201913036RA (en) 2015-02-20 2020-02-27 Incyte Corp Bicyclic heterocycles as fgfr inhibitors
AU2016257179A1 (en) 2015-05-05 2017-11-02 Pfizer Inc. 2-thiopyrimidinones
WO2017040449A1 (en) * 2015-09-03 2017-03-09 Bristol-Myers Squibb Company Triazolopyridine inhibitors of myeloperoxidase
WO2017040451A1 (en) * 2015-09-03 2017-03-09 Bristol-Myers Squibb Company Triazolopyridine inhibitors of myeloperoxidase
WO2017160632A1 (en) * 2016-03-14 2017-09-21 Bristol-Myers Squibb Company Triazolopyridine inhibitors of myeloperoxidase
AR111960A1 (en) 2017-05-26 2019-09-04 Incyte Corp CRYSTALLINE FORMS OF A FGFR INHIBITOR AND PROCESSES FOR ITS PREPARATION
EP3654983B1 (en) 2017-07-17 2023-08-30 Astrazeneca AB Mpo inhibitors for use in medicine
EP3697397A4 (en) 2017-10-19 2021-06-16 Texas State University Photoactivatable cancer prodrug
EP3788046B1 (en) 2018-05-04 2025-12-10 Incyte Corporation Salts of an fgfr inhibitor
EP4309737A3 (en) 2018-05-04 2024-03-27 Incyte Corporation Solid forms of an fgfr inhibitor and processes for preparing the same
WO2020021300A1 (en) 2018-07-24 2020-01-30 INSERM (Institut National de la Santé et de la Recherche Médicale) Use of myeloperoxidase (mpo) inhibitors for the treatment of chemoresistant acute myeloid leukemia (aml)
US11628162B2 (en) 2019-03-08 2023-04-18 Incyte Corporation Methods of treating cancer with an FGFR inhibitor
US11591329B2 (en) 2019-07-09 2023-02-28 Incyte Corporation Bicyclic heterocycles as FGFR inhibitors
WO2021013942A1 (en) 2019-07-24 2021-01-28 INSERM (Institut National de la Santé et de la Recherche Médicale) Use of myeloperoxidase inhibitors for the treatment of cardiovascular diseases in patients suffering from myeloproliferative neoplasms
WO2021067374A1 (en) 2019-10-01 2021-04-08 Incyte Corporation Bicyclic heterocycles as fgfr inhibitors
AU2020363903A1 (en) * 2019-10-10 2022-03-24 Biohaven Therapeutics Ltd. Prodrugs of myeloperoxidase inhibitors
CR20220169A (en) 2019-10-14 2022-10-27 Incyte Corp Bicyclic heterocycles as fgfr inhibitors
WO2021076728A1 (en) 2019-10-16 2021-04-22 Incyte Corporation Bicyclic heterocycles as fgfr inhibitors
CA3163875A1 (en) 2019-12-04 2021-06-10 Incyte Corporation Tricyclic heterocycles as fgfr inhibitors
KR20220131900A (en) 2019-12-04 2022-09-29 인사이트 코포레이션 Derivatives of FGFR inhibitors
US12012409B2 (en) 2020-01-15 2024-06-18 Incyte Corporation Bicyclic heterocycles as FGFR inhibitors
WO2021178734A1 (en) * 2020-03-05 2021-09-10 Biohaven Therapeutics Ltd. Method of treating amyotrophic lateral sclerosis with myeloperoxidase inhibitor
EP4114837A1 (en) 2020-03-06 2023-01-11 Bayer Aktiengesellschaft Pyrazolopyrazines acting on cancers via inhibition of cdk12
AU2021267874A1 (en) * 2020-05-06 2023-01-19 Biohaven Therapeutics Ltd. Process for the preparation of verdiperstat
EP4165034A1 (en) 2020-06-11 2023-04-19 Janssen Sciences Ireland Unlimited Company Hemi (l)-tartrate forms of 3-({5-chloro-1-[3-(methylsulfonyl)propyl]-1h-indol-2 yl} methyl)-1-(2,2,2-trifluoroethyl)-1,3-dihydro-2h-imidazo[4,5-c]pyridin-2-one and pharmaceutical compositions comprising the same
US12065494B2 (en) 2021-04-12 2024-08-20 Incyte Corporation Combination therapy comprising an FGFR inhibitor and a Nectin-4 targeting agent
CN115403584B (en) * 2021-05-26 2024-04-02 长春金赛药业有限责任公司 2-thio-2, 3-dihydropyrimidine-4-one derivatives, pharmaceutical compositions, preparation methods and applications thereof
AR126102A1 (en) 2021-06-09 2023-09-13 Incyte Corp TRICYCLIC HETEROCYCLES AS FGFR INHIBITORS
AR126101A1 (en) 2021-06-09 2023-09-13 Incyte Corp TRICYCLIC HETEROCYCLES AS FGFR INHIBITORS
JP2025528217A (en) 2022-08-18 2025-08-26 アストラゼネカ・アクチエボラーグ Myeloperoxidase inhibitors
CN120265633A (en) * 2022-12-09 2025-07-04 深圳信立泰药业股份有限公司 A pyrrolo[3,2-d]pyrimidin-4-one derivative and its preparation method and medical use
WO2025107036A1 (en) * 2023-11-23 2025-05-30 Syntara Limited Dual inhibitors of amine oxidases and peroxidases, and uses thereof
WO2025172474A1 (en) 2024-02-15 2025-08-21 Astrazeneca Ab Inhibitors of myeloperoxidase
WO2025190901A1 (en) 2024-03-13 2025-09-18 Institut National de la Santé et de la Recherche Médicale Use of myeloperoxidase (mpo) inhibitors for promoting cd8+ t cell responses

Family Cites Families (56)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3135753A (en) 1961-05-10 1964-06-02 Burroughs Wellcome Co Alkylthiopurines and method
US3652579A (en) * 1969-06-26 1972-03-28 Hoffmann La Roche 1-methyl-2-substituted 5-nitroimidazoles
SE7810947L (en) 1978-10-20 1980-04-21 Draco Ab 3-ALKYLXANTHINES
US4710503A (en) 1985-02-07 1987-12-01 Euroceltique S.A. 6-thioxanthine derivatives
WO1989006125A1 (en) 1987-12-31 1989-07-13 Smithkline Beckman Corporation 4-aralkyl-5-substituted-1,2,4-triazole-5-thiols
DK440989A (en) 1988-09-12 1990-03-13 Smithkline Beecham Corp DOPAMINE-BETA-HYDROXYLASE INHIBITORS
JPH02160235A (en) 1988-12-13 1990-06-20 Konica Corp Process for forming silver halide color photographic picture image
EP0430300A3 (en) 1989-12-01 1992-03-25 Takeda Chemical Industries, Ltd. Xanthine derivatives, their production and use
US5100906A (en) 1990-04-19 1992-03-31 Merrell Dow Pharmaceuticals Inc. 5-aryl-4-alkyl-3h-1,2,4-triazole-3-thiones useful as memory enhancers
FR2665636B1 (en) 1990-08-10 1994-10-07 Adir USE OF A TRIMETHYL-1,3,7 XANTHINE DERIVATIVE FOR THE TREATMENT OF MEMORY DISORDERS, INTELLECTUAL DISORDERS OF SENESCENCE AND ALZHEIMER'S DISEASE.
US6046019A (en) 1991-07-09 2000-04-04 Goumeniouk; Alexander P. Diagnostic kits and methods for making granulocyte cell counts
US5281209A (en) 1992-06-30 1994-01-25 The Procter & Gamble Company Absorbent article having tucked flaps
AU4276693A (en) 1992-04-21 1993-11-18 Biocryst Pharmaceuticals, Inc. 7-disubstituted-methyl-4-oxo-3H,5H-pyrrolo(3,2-d)pyrim idine and pharmaceutical uses and compositions containing the same
US6469017B1 (en) 1998-01-16 2002-10-22 Cell Therapeutics, Inc. Method of inhibiting interleukin-12 signaling
GB9312853D0 (en) 1993-06-22 1993-08-04 Euro Celtique Sa Chemical compounds
PL314605A1 (en) 1993-11-26 1996-09-16 Pfizer Isoxazolin compounds as anti-inflammatory agents
US5489598A (en) 1994-06-08 1996-02-06 Warner-Lambert Company Cytoprotection utilizing aryltriazol-3-thiones
CA2206287C (en) 1994-12-13 2001-03-20 Mark Chasin Aryl thioxanthines
WO1996018400A1 (en) 1994-12-13 1996-06-20 Euro-Celtique, S.A. Trisubstituted thioxanthines
US6025361A (en) 1994-12-13 2000-02-15 Euro-Celtique, S.A. Trisubstituted thioxanthines
US5756511A (en) 1995-04-03 1998-05-26 Cell Therapeutics, Inc. Method for treating symptoms of a neurodegenerative condition
US6294541B1 (en) 1996-06-06 2001-09-25 Euro-Celtique S.A. Purine derivatives having phosphodiesterase IV inhibition activity
GB9626643D0 (en) 1996-12-21 1997-02-12 Astra Pharma Prod Compounds
US5976823A (en) 1997-03-19 1999-11-02 Integrated Biomedical Technology, Inc. Low range total available chlorine test strip
WO1999012546A1 (en) 1997-09-05 1999-03-18 Kyowa Hakko Kogyo Co., Ltd. Remedial agent for neural degeneration
WO1999014204A1 (en) 1997-09-16 1999-03-25 G.D. Searle & Co. Substituted 1,2,4-triazoles useful for inhibiting cholesteryl ester transfer protein activity
AR013669A1 (en) 1997-10-07 2001-01-10 Smithkline Beecham Corp COMPOUNDS AND METHODS
US6187777B1 (en) * 1998-02-06 2001-02-13 Amgen Inc. Compounds and methods which modulate feeding behavior and related diseases
US6319928B1 (en) 1998-11-30 2001-11-20 Euro-Celtique, S.A. Purine derivatives having phosphodiesterase IV inhibition activity
DZ3019A1 (en) 1999-03-01 2005-05-20 Smithkline Beecham Corp Use of a pde4 inhibitor in the preparation of a drug against copd.
JP2002541078A (en) * 1999-04-02 2002-12-03 ユーロ−セルティーク，エス．エー． Purine derivatives having phosphodiesterase IV inhibitory activity
GB2362101A (en) 2000-05-12 2001-11-14 Astrazeneca Ab Treatment of chronic obstructive pulmonary disease
FR2811989A1 (en) 2000-07-18 2002-01-25 Sanofi Synthelabo POLYFLUOROALKYTRIAZOLE DERIVATIVES, THEIR PREPARATION AND THEIR THERAPEUTIC USE
US6855817B2 (en) 2000-07-21 2005-02-15 Mark B. Lyles Materials and methods for binding nucleic acids to surfaces
GB0100623D0 (en) 2001-01-10 2001-02-21 Vernalis Res Ltd Chemical compounds IV
GB0100620D0 (en) 2001-01-10 2001-02-21 Vernalis Res Ltd Chemical cokpounds V
FR2819723B1 (en) 2001-01-23 2006-11-17 Arnaud Mainnemare HALOGEN COMPOSITION, PREPARATION METHOD AND USES THEREOF
WO2002066447A1 (en) 2001-02-21 2002-08-29 Ono Pharmaceutical Co., Ltd. 4h-1,2,4-triazole-3(2h)-thione deratives as sphingomyelinase inhibitors
SE0103766D0 (en) 2001-11-09 2001-11-09 Astrazeneca Ab Novel assay
JP4095446B2 (en) 2001-05-08 2008-06-04 アストラゼネカ・アクチエボラーグ An assay to detect inhibitors of the enzyme myeloperoxidase
ES2193839B1 (en) 2001-06-22 2005-02-16 Almirall Prodesfarma, S.A. NEW DERIVATIVES OF 6-PHENYLDIHYDROPIRROLPIRIMIDINDIONA.
AU2003207734C1 (en) 2002-01-28 2009-10-08 Kyowa Kirin Co., Ltd. Methods of treating patients suffering from movement disorders
ES2208063B1 (en) * 2002-04-01 2005-10-01 Almirall Prodesfarma, S.A. NEW DERIVATIVES OF THE 4- (PIRROLOPIRIMIDIN-6-IL) BENCENOSULFONAMIDE.
AR039385A1 (en) 2002-04-19 2005-02-16 Astrazeneca Ab THIOXANTINE DERIVATIVES AS INHIBITORS OF MIELOPEROXIDASA
SE0301232D0 (en) 2003-04-25 2003-04-25 Astrazeneca Ab Novel use
SE0302756D0 (en) * 2003-10-17 2003-10-17 Astrazeneca Ab Novel Compounds
MXPA06004789A (en) * 2003-10-31 2006-07-03 Cv Therapeutics Inc A2b adenosine receptor antagonists.
BRPI0507604A (en) 2004-02-14 2007-07-03 Smithkline Beecham Corp medicines with hm74a receptor activity
WO2006045564A1 (en) 2004-10-22 2006-05-04 Smithkline Beecham Corporation Xanthine derivatives with hm74a receptor activity
SE0402591D0 (en) 2004-10-25 2004-10-25 Astrazeneca Ab Novel use
MY140748A (en) 2004-12-06 2010-01-15 Astrazeneca Ab Novel pyrrolo [3,2-d] pyrimidin-4-one derivatives and their use in therapy
UY30267A1 (en) 2006-04-13 2007-11-30 Astrazeneca Ab NEW DERIVATIVES OF THIOXANTINE, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM, PREPARATION PROCEDURES AND APPLICATIONS
TW200804383A (en) 2006-06-05 2008-01-16 Astrazeneca Ab New compounds
US20090124640A1 (en) 2006-06-05 2009-05-14 Astrazeneca Ab Pyrrolo[3,2-D]Pyrimidin-4-One Derivative as Myeloperoxidase Inhibitor
AR066936A1 (en) 2007-06-13 2009-09-23 Astrazeneca Ab 3 - (2R - TETRAHYDROFURIL - METHYL) - 2 - THIOXANTINE. PHARMACEUTICAL COMPOSITIONS.
US20090054468A1 (en) 2007-08-23 2009-02-26 Astrazeneca Ab New Use 938

Also Published As

Publication number Publication date
SA05260385B1 (en) 2009-02-25
AU2005312388B2 (en) 2009-10-29
CN101072778A (en) 2007-11-14
TWI365189B (en) 2012-06-01
RU2007119307A (en) 2009-01-20
KR101557715B1 (en) 2015-10-06
UY29246A1 (en) 2006-08-31
RU2577858C2 (en) 2016-03-20
AU2005312388A1 (en) 2006-06-15
IL183182A (en) 2012-02-29
AR051698A1 (en) 2007-01-31
KR101412939B1 (en) 2014-06-26
US20110059996A1 (en) 2011-03-10
ES2390888T3 (en) 2012-11-19
BRPI0518846B1 (en) 2022-04-05
KR20140010177A (en) 2014-01-23
US9580429B2 (en) 2017-02-28
ME01486B (en) 2014-04-20
US20150099769A1 (en) 2015-04-09
CA2591314A1 (en) 2006-06-15
KR20130037236A (en) 2013-04-15
RU2409578C2 (en) 2011-01-20
MY140748A (en) 2010-01-15
JP2008522968A (en) 2008-07-03
UA89968C2 (en) 2010-03-25
NZ555046A (en) 2010-08-27
US8859568B2 (en) 2014-10-14
HK1110859A1 (en) 2008-07-25
EP1824855B1 (en) 2012-08-08
BRPI0518846A2 (en) 2008-12-09
PT1824855E (en) 2012-10-09
EP1824855A4 (en) 2010-12-08
PL1824855T3 (en) 2012-11-30
US7829707B2 (en) 2010-11-09
TW200626601A (en) 2006-08-01
US20080221136A1 (en) 2008-09-11
IL183182A0 (en) 2007-09-20
JP5028270B2 (en) 2012-09-19
SI1824855T1 (en) 2012-11-30
HRP20120781T1 (en) 2012-10-31
CY1113209T1 (en) 2016-04-13
DK1824855T3 (en) 2012-10-15
KR20070090178A (en) 2007-09-05
CA2591314C (en) 2011-06-21
RU2010139806A (en) 2012-04-10
RS52490B (en) 2013-02-28
CN101072778B (en) 2011-06-15
MX2007006497A (en) 2007-06-22
EP1824855A1 (en) 2007-08-29
KR101412786B1 (en) 2014-06-30
WO2006062465A1 (en) 2006-06-15

Similar Documents

Publication Publication Date Title
NO20072399L (en) New pyrrolo [3,2-d] pyrimidin-4-o derivatives and their use in therapy
NO20075059L (en) Novel compounds II 2-pyridine derivatives as inhibitors of neutrophil elastase
NO20061454L (en) Compounds having CRTH2 antagonist activity
NO20084845L (en) 2-pyrazinone derivatives for the treatment of disease or conditions where inhibition of neutrophil elastase activity is beneficial
NO20072259L (en) Heteroarylthiazoles and their use as P13K inhibitors
NO20052805L (en) Substituted pyrrolo-pyrazole derivatives as kinase inhibitors
NO20084872L (en) 2-pyridone derivatives for the treatment of disease or conditions where inhibition of neutrophil elastase activity is beneficial
NO20062136L (en) Imidazopyrazintyrosin kinase inhibitors
NO20061700L (en) 2-pyridone derivatives as neutrophil elastase inhibitors and their use
NO20061660L (en) 2-pyridone derivatives as neutrophil elasae inhibitor and their use
NO20045677L (en) Inhibitors of JAK and CDK2 protein kinases
NO20055496L (en) Pyrazoloquinazoline derivatives, methods for their preparation and their use as kinase inhibitors
NO20062591L (en) Diphenyllazetidinone derivatives with cholesterol absorption inhibitory activity
NO20062583L (en) Diphenyllazetidinone derivatives with cholesterol absorption inhibitory activity
NO20076066L (en) Oxadiazole derivatives as DGAT inhibitors
NO20076054L (en) Imidiazo and triazolopyridines as inhibitors of 11-beta-hydroxysteroid dehydrogenase type I
NO20080675L (en) P38-Map kinase inhibitors and methods for their use
NO20073140L (en) Pyrrolopyrazines and pyralopyrazines useful as inhibitors of protein kinases
NO20076658L (en) Heteroberl benzamide derivatives for use as GLK activators in the treatment of diabetes
NO20084418L (en) Azolopyridin-3-one derivatives as inhibitors of endothelial lipase
NO20064000L (en) Heteroeryl-linked pyrazolo derivatives
NO20082414L (en) Inhibitors of AKT activity
NO20044592L (en) Aryl ketone pyrrolotriazine compounds useful as kinase inhibitors
NO20071246L (en) Quinazolinone derivatives and their use as B-RAF inhibitors.
NO20082496L (en) pyrazine derivatives